These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 8649855)

  • 21. Reactivation of mutant p53: molecular mechanisms and therapeutic potential.
    Selivanova G; Wiman KG
    Oncogene; 2007 Apr; 26(15):2243-54. PubMed ID: 17401433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein.
    Vojtesek B; Dolezalova H; Lauerova L; Svitakova M; Havlis P; Kovarik J; Midgley CA; Lane DP
    Oncogene; 1995 Jan; 10(2):389-93. PubMed ID: 7530828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interactions of mutant p53 with DNA: guilt by association.
    Kim E; Deppert W
    Oncogene; 2007 Apr; 26(15):2185-90. PubMed ID: 17401427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. On the mechanism of sequence-specific DNA-dependent acetylation of p53: the acetylation motif is exposed upon DNA binding.
    Cesková P; Chichger H; Wallace M; Vojtesek B; Hupp TR
    J Mol Biol; 2006 Mar; 357(2):442-56. PubMed ID: 16438982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The DNA binding activity of wild type p53 is modulated by blocking its various antigenic epitopes.
    Wolkowicz R; Elkind NB; Ronen D; Rotter V
    Oncogene; 1995 Mar; 10(6):1167-74. PubMed ID: 7535417
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Restoration of the transcription activation function to mutant p53 in human cancer cells.
    Abarzúa P; LoSardo JE; Gubler ML; Spathis R; Lu YA; Felix A; Neri A
    Oncogene; 1996 Dec; 13(11):2477-82. PubMed ID: 8957091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The N terminus of the murine p53 tumour suppressor is an independent regulatory domain affecting activation and thermostability.
    Hansen S; Lane DP; Midgley CA
    J Mol Biol; 1998 Jan; 275(4):575-88. PubMed ID: 9466932
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Specific and complex interactions of murine p53 with DNA.
    Weissker SN; Müller BF; Homfeld A; Deppert W
    Oncogene; 1992 Oct; 7(10):1921-32. PubMed ID: 1408133
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cognate DNA stabilizes the tumor suppressor p53 and prevents misfolding and aggregation.
    Ishimaru D; Ano Bom AP; Lima LM; Quesado PA; Oyama MF; de Moura Gallo CV; Cordeiro Y; Silva JL
    Biochemistry; 2009 Jul; 48(26):6126-35. PubMed ID: 19505151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulation of specific DNA binding by p53: evidence for a role for O-glycosylation and charged residues at the carboxy-terminus.
    Shaw P; Freeman J; Bovey R; Iggo R
    Oncogene; 1996 Feb; 12(4):921-30. PubMed ID: 8632915
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elevated expression of ribosomal protein genes L37, RPP-1, and S2 in the presence of mutant p53.
    Loging WT; Reisman D
    Cancer Epidemiol Biomarkers Prev; 1999 Nov; 8(11):1011-6. PubMed ID: 10566557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Target gene modulation in hepatocellular carcinomas by decreased DNA-binding of p53 mutations.
    Kubicka S; Trautwein C; Niehof M; Manns M
    Hepatology; 1997 Apr; 25(4):867-73. PubMed ID: 9096590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Restoring wild-type conformation and DNA-binding activity of mutant p53 is insufficient for restoration of transcriptional activity.
    Brazda V; Muller P; Brozkova K; Vojtesek B
    Biochem Biophys Res Commun; 2006 Dec; 351(2):499-506. PubMed ID: 17070499
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncogenic mutation of the p53 gene derived from head and neck cancer prevents cells from undergoing apoptosis after DNA damage.
    Kawamata H; Omotehara F; Nakashiro K; Uchida D; Shinagawa Y; Tachibana M; Imai Y; Fujimori T
    Int J Oncol; 2007 May; 30(5):1089-97. PubMed ID: 17390010
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interaction of human polyomavirus BK with the tumor-suppressor protein p53.
    Shivakumar CV; Das GC
    Oncogene; 1996 Jul; 13(2):323-32. PubMed ID: 8710371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. p53 mutants without a functional tetramerisation domain are not oncogenic.
    Chène P; Bechter E
    J Mol Biol; 1999 Mar; 286(5):1269-74. PubMed ID: 10064694
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Redox modulation of p53 conformation and sequence-specific DNA binding in vitro.
    Hainaut P; Milner J
    Cancer Res; 1993 Oct; 53(19):4469-73. PubMed ID: 8402615
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional quantification of DNA-binding proteins p53 and estrogen receptor in cells and tumor tissues by DNA affinity immunoblotting.
    Liu Y; Asch H; Kulesz-Martin MF
    Cancer Res; 2001 Jul; 61(14):5402-6. PubMed ID: 11454683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of genomic DNA sequences bound by mutant p53 protein (Gly245-->Ser) in vivo.
    Koga H; Deppert W
    Oncogene; 2000 Aug; 19(36):4178-83. PubMed ID: 10962580
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutants of the tumour suppressor p53 L1 loop as second-site suppressors for restoring DNA binding to oncogenic p53 mutations: structural and biochemical insights.
    Merabet A; Houlleberghs H; Maclagan K; Akanho E; Bui TT; Pagano B; Drake AF; Fraternali F; Nikolova PV
    Biochem J; 2010 Mar; 427(2):225-36. PubMed ID: 20113312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.